139 related articles for article (PubMed ID: 29588598)
1. Measurement of serum PODXL concentration for detection of pancreatic cancer.
Taniuchi K; Tsuboi M; Sakaguchi M; Saibara T
Onco Targets Ther; 2018; 11():1433-1445. PubMed ID: 29588598
[TBL] [Abstract][Full Text] [Related]
2. [Measurement of PODXL and SCGB1D2 for detecting intraductal papillary mucinous neoplasm].
Taniuchi K; Okabayashi T; Sakaguchi M; Iwata J
Nihon Shokakibyo Gakkai Zasshi; 2021; 118(3):235-244. PubMed ID: 33692257
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
4. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
5. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of PODXL/ITGB1 and BCL7B/ITGB1 accurately predicts unfavorable prognosis compared to the TNM staging system in postoperative pancreatic cancer patients.
Taniuchi K; Furihata M; Naganuma S; Sakaguchi M; Saibara T
PLoS One; 2019; 14(6):e0217920. PubMed ID: 31166991
[TBL] [Abstract][Full Text] [Related]
7. Podocalyxin-like protein, linked to poor prognosis of pancreatic cancers, promotes cell invasion by binding to gelsolin.
Taniuchi K; Furihata M; Naganuma S; Dabanaka K; Hanazaki K; Saibara T
Cancer Sci; 2016 Oct; 107(10):1430-1442. PubMed ID: 27461278
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma.
Heby M; Elebro J; Nodin B; Jirström K; Eberhard J
BMC Clin Pathol; 2015; 15():10. PubMed ID: 26028992
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.
Ritchie SA; Chitou B; Zheng Q; Jayasinghe D; Jin W; Mochizuki A; Goodenowe DB
World J Gastroenterol; 2015 Jun; 21(21):6604-12. PubMed ID: 26074698
[TBL] [Abstract][Full Text] [Related]
10. Serum podocalyxin levels correlate with carotid intima media thickness, implicating its role as a novel biomarker for atherosclerosis.
Shoji M; Takemoto M; Kobayashi K; Shoji T; Mori S; Sagara JI; Kurosawa H; Hirayama Y; Sakamoto K; Ishikawa T; Koshizaka M; Maezawa Y; Yokote K
Sci Rep; 2018 Jan; 8(1):245. PubMed ID: 29321582
[TBL] [Abstract][Full Text] [Related]
11. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic Cancer Insights: Optimization of the Diagnostic Capacity of Tumor Biomarkers.
Delgado JA; Ballesteros MA; Parera MM; Bauça JM
Lab Med; 2021 Nov; 52(6):550-557. PubMed ID: 33900408
[TBL] [Abstract][Full Text] [Related]
13. Podocalyxin is a marker of poor prognosis in colorectal cancer.
Kaprio T; Fermér C; Hagström J; Mustonen H; Böckelman C; Nilsson O; Haglund C
BMC Cancer; 2014 Jul; 14():493. PubMed ID: 25004863
[TBL] [Abstract][Full Text] [Related]
14. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
[TBL] [Abstract][Full Text] [Related]
15. Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.
Boman K; Andersson G; Wennersten C; Nodin B; Ahlgren G; Jirström K
Biomark Res; 2017; 5():10. PubMed ID: 28293425
[TBL] [Abstract][Full Text] [Related]
16. Serum miR-1290 and miR-1246 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer.
Wei J; Yang L; Wu YN; Xu J
J Cancer; 2020; 11(6):1325-1333. PubMed ID: 32047539
[No Abstract] [Full Text] [Related]
17. A cancer-specific anti-podocalyxin monoclonal antibody (60-mG
Kaneko MK; Ohishi T; Kawada M; Kato Y
Biochem Biophys Rep; 2020 Dec; 24():100826. PubMed ID: 33088928
[TBL] [Abstract][Full Text] [Related]
18. Application of miR-193a/WT1/PODXL axis to estimate risk and prognosis of idiopathic membranous nephropathy.
Zhang W; Ren Y; Li J
Ren Fail; 2019 Nov; 41(1):704-717. PubMed ID: 31352863
[No Abstract] [Full Text] [Related]
19. Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer.
Larsson A; Fridberg M; Gaber A; Nodin B; Levéen P; Jönsson G; Uhlén M; Birgisson H; Jirström K
BMC Cancer; 2012 Jul; 12():282. PubMed ID: 22769594
[TBL] [Abstract][Full Text] [Related]
20. Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer.
Kitagawa T; Taniuchi K; Tsuboi M; Sakaguchi M; Kohsaki T; Okabayashi T; Saibara T
Mol Oncol; 2019 Feb; 13(2):212-227. PubMed ID: 30358104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
